The global retinal vein occlusion (RVO) treatment market, valued at USD 2.3 billion in 2023, is poised for substantial growth, with a compound annual growth rate (CAGR) of 5.9% projected over the forecast period. By 2033, the market is anticipated to reach USD 4.7 billion, driven by rising demand for advanced therapies and an aging global population.
Retinal vein occlusion, one of the most common retinal vascular disorders among older adults, predominantly affects individuals aged 65 and above. Age is a significant risk factor, and the growing geriatric population worldwide is expected to contribute to an increased incidence of the condition, further fueling demand for innovative treatment options.
Technological advancements in diagnostic tools and therapeutic approaches, including anti-VEGF (vascular endothelial growth factor) treatments and corticosteroid injections, are enhancing patient outcomes. These developments, coupled with increased healthcare accessibility, are bolstering the market’s expansion.
Get the Comprehensive Full Report Now – https://www.futuremarketinsights.com/reports/retinal-vein-occlusion-treatment-market
Key Takeaways:
- The retinal vein occlusion treatment market is projected to grow at a 5.9% CAGR, doubling from USD 2.3 billion in 2023 to USD 4.7 billion by 2033.
- The aging population is a key driver, as individuals over 65 are at higher risk for RVO.
- Advancements in anti-VEGF therapies and diagnostic technologies are improving treatment efficacy and driving market demand.
- The rising prevalence of retinal vascular disorders underscores the need for continued innovation and investment in RVO treatment solutions.
Market Drivers
- Aging Population: The demographic shift towards an older population is a primary driver for the increasing prevalence of retinal vein occlusion, as older individuals are more susceptible to this condition.
- Rising Incidence of Chronic Conditions: The growing prevalence of diabetes and hypertension, which are significant risk factors for RVO, is contributing to market expansion.
- Advancements in Treatment Options: Continuous innovations in treatment modalities, including anti-VEGF therapies and corticosteroids, are enhancing the effectiveness of RVO management.
- Increased Awareness and Screening: Growing awareness about eye health and advancements in diagnostic technologies are leading to earlier detection and treatment of RVO.
Regional Insights
- North America is anticipated to hold a substantial share of the market, driven by advanced healthcare infrastructure and high rates of diagnosis and treatment.
- The Asia-Pacific region is poised for rapid growth due to increasing healthcare investments and rising awareness about retinal diseases.
Market Competition
Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc, Chugai Pharmaceuticals, Novartis AG. Some of the latest developments by the manufacturers are below
- Novartis AG stated highly supportive of the initial interpretable Phase III outcomes of a clinical study examining the efficacy and security of Beovu in December 2020. Beovu by Novartis put Regeneron’s anti-VEGF Eylea, one of the renowned treatments for diabetic macular edema, in direct competition.
- Roche is presently conducting Phase III trials to determine the effectiveness and security of Faricimab in patient populations with macular edema secondary to BRVO and CRVO, with the drug anticipated to be approved by 2023 according to the findings.
Key Companies Profiled
- AbbVie
- F. Hoffmann- La Roche AG
- Regeneron Pharmaceuticals Inc.
- Taiwan Liposome Company
- Aerie Pharmaceuticals Inc.
- Graybug Vision
- Outlook Therapeutics
- Kodiak Sciences Inc.
- Chugai Pharmaceutical Co. Ltd.
- Novartis AG
Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey
By Drug Class:
- Ranibizumab
- Dexamethasone
- Aflibercept
- Bevacizumab
By Type:
- Central Retinal Vein Occlusion
- Branch Retinal Vein Occlusion
By Diagnosis:
- Optical Coherence Tomography
- Fundoscopic Examination
- Fluorescein Angiography
By End User:
- Hospitals
- Research and Academics
- Specialty Clinics
By Region:
- North America
- Europe
- East Asia
- South Asia
- Oceania
- Latin America
- Middle East and Africa (MEA)
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube